NCT03166345 (PRPITM) is a NA clinical trial of Treatment of Thin Endometrium in Poor Endometrium, sponsored by Ibn Sina Hospital.

Who is sponsoring NCT03166345?

NCT03166345 is sponsored by Ibn Sina Hospital.

What drugs are being tested in NCT03166345?

Interventions in NCT03166345: Treatment of Thin Endometrium.

What condition does NCT03166345 study?

NCT03166345 studies Poor Endometrium.

Is NCT03166345 still recruiting?

NCT03166345 is currently completed. Last updated 12 July 2018.

Last reviewed 2018-07-12 · How we verify

NCT03166345: PRPITM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of Platelet Rich Plasma (PRP) for Improving Thin Endometrium

Completed NA Last updated 12 July 2018

What this trial tests

NA trial testing Treatment of Thin Endometrium in Poor Endometrium in 150 participants. Completed in 1 April 2018.

Timeline

15 August 2017

Primary endpoint
30 March 2018

1 April 2018

Quick facts

Lead sponsor	Ibn Sina Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	150
Start date	15 August 2017
Primary completion	30 March 2018
Estimated completion	1 April 2018
Sites	2 locations across Egypt

Drugs / interventions tested

Treatment of Thin Endometrium

Conditions studied

Poor Endometrium — all drugs for Poor Endometrium →

Sponsor

Ibn Sina Hospital

Who can join

Adults 18 to 40, female only, with Poor Endometrium. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Platelets rich plasma is simple source of growth factors and cytokines that can regulate endometrial growth for subgroup of thin endometrium women. It is an autologous source of this enhancing factors; therefore, there os no risk of using it within the same participant.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Autologous platelet-rich plasma for assisted reproduction.
Vaidakis D, Papapanou M, Siristatidis CS. · · 2024 · cited 20× · PMID 38682756 · DOI 10.1002/14651858.cd013875.pub2
Therapeutic roles of platelet-rich plasma to restore female reproductive and endocrine dysfunction.
Wang X, Li J, Lu W, Gao F, et al · · 2024 · cited 8× · PMID 38654928 · DOI 10.3389/fendo.2024.1374382

Verify or expand the search:

Other Ibn Sina Hospital trials

Trials by the same sponsor.

NCT02896777 — Triple-arm pH Comparison · NA · completed
NCT06503835 — Efficacy of Transforaminal Epidural Steroid and Its Combination With Ozone in Lumbar Radiculopathy · completed
NCT04210414 — Cleave-stage Transfer on Day 3 Versus Day 5 Transfer When Only One Embryo Available · NA · terminated
NCT04052607 — Progestin Priming Ovarian Stimulation (PPOS) Compared With Antagonist Protocol for Freeze-all Cycles · NA · terminated
NCT03823235 — Humidified Culture and Live Birth After ICSI · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03166345 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ibn Sina Hospital
Last refreshed: 12 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03166345.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing